PI3K-independent AKT Activation in Cancers: a Treasure Trove for Novel Therapeutics

Overview

Journal J Cell Physiol

Specialties Cell Biology
Physiology

Date 2012 Feb 7

PMID 22307544

Citations 112

Authors

Kiran Mahajan

Nupam P Mahajan

Affiliations

Soon will be listed here.

Abstract

AKT/PKB serine threonine kinase, a critical signaling molecule promoting cell growth and survival pathways, is frequently dysregulated in many cancers. Although phosphatidylinositol-3-OH kinase (PI3K), a lipid kinase, is well characterized as a major regulator of AKT activation in response to a variety of ligands, recent studies highlight a diverse group of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine (TBK1, IKBKE, DNAPKcs) kinases that activate AKT directly to promote its pro-proliferative signaling functions. While some of these alternate AKT activating kinases respond to growth factors, others respond to inflammatory and genotoxic stimuli. A common theme emerging from these studies is that aberrant or hyperactivation of these alternate kinases is often associated with malignancy. Consequently, evaluating the use of small molecular inhibitors against these alternate AKT activating kinases at earlier stages of cancer therapy may overcome the pressing problem of drug resistance surfacing especially in patients treated with PI3K inhibitors.

Citing Articles

IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway.

Liu S, Li J, Zhang J, Wan F, Hong Z, Hong Z Int J Biol Sci. 2024; 20(15):6146-6161.

PMID: 39664571 PMC: 11628342. DOI: 10.7150/ijbs.102666.

miR-122/NEGR1 axis contributes colorectal cancer liver metastasis by PI3K/AKT pathway and macrophage modulation.

Dai S, Zhuang H, Li Z, Chen Z, Chai Y, Zhou Q J Transl Med. 2024; 22(1):1060.

PMID: 39587606 PMC: 11590399. DOI: 10.1186/s12967-024-05901-5.

Human Disabled-2 regulates thromboxane A signaling for efficient hemostasis in thrombocytopenia.

Tsai H, Chang Y, Hsieh Y, Wang J, Wu C, Ho M Nat Commun. 2024; 15(1):9816.

PMID: 39537612 PMC: 11561248. DOI: 10.1038/s41467-024-54093-5.

Cytotoxic Autophagy: A Novel Treatment Paradigm against Breast Cancer Using Oleanolic Acid and Ursolic Acid.

Gupta K, Gao J, Li X, Thangaraju M, Panda S, Lokeshwar B Cancers (Basel). 2024; 16(19).

PMID: 39409987 PMC: 11476055. DOI: 10.3390/cancers16193367.

Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.

Prasad D, Baldelli E, Blais E, Davis J, El Gazzah E, Mueller C Br J Cancer. 2024; 131(9):1543-1554.

PMID: 39322687 PMC: 11519601. DOI: 10.1038/s41416-024-02852-y.

References

Xie X, Zhang D, Zhao B, Lu M, You M, Condorelli G . IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A. 2011; 108(16):6474-9. PMC: 3081021. DOI: 10.1073/pnas.1016132108. View

Clark K, Plater L, Peggie M, Cohen P . Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem. 2009; 284(21):14136-46. PMC: 2682862. DOI: 10.1074/jbc.M109.000414. View

Jiang T, Qiu Y . Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem. 2003; 278(18):15789-93. DOI: 10.1074/jbc.M212525200. View

Chen R, Kim O, Yang J, Sato K, Eisenmann K, McCarthy J . Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem. 2001; 276(34):31858-62. DOI: 10.1074/jbc.C100271200. View

tenOever B, Ng S, Chua M, McWhirter S, Garcia-Sastre A, Maniatis T . Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science. 2007; 315(5816):1274-8. DOI: 10.1126/science.1136567. View

Barbie D, Tamayo P, Boehm J, Kim S, Moody S, Dunn I . Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462(7269):108-12. PMC: 2783335. DOI: 10.1038/nature08460. View

Franke T, Yang S, Chan T, Datta K, Kazlauskas A, Morrison D . The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995; 81(5):727-36. DOI: 10.1016/0092-8674(95)90534-0. View

Dong L, Liu F . PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab. 2005; 289(2):E187-96. DOI: 10.1152/ajpendo.00011.2005. View

Gellert M . V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem. 2002; 71:101-32. DOI: 10.1146/annurev.biochem.71.090501.150203. View

10.

Garner K, Pletnev A, Eastman A . Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2009; 5(3):129-30. PMC: 3881006. DOI: 10.1038/nchembio0309-129. View

11.

Green T, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J . Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009; 3(3):248-61. PMC: 5527863. DOI: 10.1016/j.molonc.2009.01.002. View

12.

Mahajan N, Whang Y, Mohler J, Earp H . Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res. 2005; 65(22):10514-23. DOI: 10.1158/0008-5472.CAN-05-1127. View

13.

Bose S, Chandran S, Mirocha J, Bose N . The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2005; 19(2):238-45. DOI: 10.1038/modpathol.3800525. View

14.

Cheng J, Godwin A, Bellacosa A, Taguchi T, Franke T, Hamilton T . AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992; 89(19):9267-71. PMC: 50107. DOI: 10.1073/pnas.89.19.9267. View

15.

Burgering B, Coffer P . Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995; 376(6541):599-602. DOI: 10.1038/376599a0. View

16.

Pomerantz J, Baltimore D . NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 1999; 18(23):6694-704. PMC: 1171732. DOI: 10.1093/emboj/18.23.6694. View

17.

Muellner M, Uras I, Gapp B, Kerzendorfer C, Smida M, Lechtermann H . A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol. 2011; 7(11):787-93. PMC: 3306898. DOI: 10.1038/nchembio.695. View

18.

Panigrahi A, Pinder S, Chan S, Paish E, Robertson J, Ellis I . The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004; 204(1):93-100. DOI: 10.1002/path.1611. View

19.

Hennequin L, Allen J, Breed J, Curwen J, Fennell M, Green T . N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006; 49(22):6465-88. DOI: 10.1021/jm060434q. View

20.

Guo J, Coppola D, Cheng J . IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem. 2011; 286(43):37389-98. PMC: 3199486. DOI: 10.1074/jbc.M111.287433. View